---
company: Lucid Diagnostics Inc.
ticker: LUCD
form: 8-K
filed: 2026-08-13
accession: 0001493152-26-037596
source: https://www.sec.gov/Archives/edgar/data/1799011/000149315226037596/
---

# Lucid Diagnostics (LUCD) earnings release, August 13, 2026

Lucid Diagnostics Inc. (LUCD) · Form 8-K, Item 2.02 · Filed 2026-08-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1799011/000149315226037596/)

Exhibit

99.1

Lucid

Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Recognized

2Q26 revenue of $1.5 million

Processed

2,770 EsoGuard® tests

Secured first laboratory benefit manager (LBM) EsoGuard coverage policy

Conference call and webcast to be held today, August 13, at 8:30 AM EDT

NEW

YORK, August 13, 2026 -

Lucid Diagnostics Inc.

(Nasdaq: LUCD)

(“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) (“PAVmed”), today provided a business update for the Company and reported financial results for the second quarter ended June 30, 2026.

Conference

Call and Webcast

The webcast will take place on Thursday, August 13, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company’s website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid

Diagnostics Business Update” to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at luciddx.com.

Business

Highlights

“Lucid’s commercial momentum strengthened throughout the second quarter and in recent weeks,” said

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer.

“We continue to advance multiple commercial priorities while awaiting a positive draft Medicare coverage policy for EsoGuard. We secured positive commercial coverage policies, accelerated engagement with the VA and major health systems, and demonstrated the long-term economic value of EsoGuard testing. Progress across these initiatives positions Lucid to capitalize on EsoGuard’s significant clinical and commercial opportunity, while increasing the company’s visibility and thereby expanding opportunities for broader strategic engagement.”

Highlights from the second quarter and recent weeks

:

Financial

Results

Lucid

Non-GAAP Measures¹

Included in general and administrative expenses in the financial statements.²

Included in other income and expenses.³

Stock-based compensation (“SBC”) expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:

About

Lucid Diagnostics

Lucid

Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.

Lucid’s EsoGuard®

Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck®

Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.

Forward-Looking

Statements

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics’ management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics’ common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics’ products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics’ clinical and preclinical studies; whether and when Lucid Diagnostics’ products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics’ products once cleared and commercialized; Lucid Diagnostics’ ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics’ control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics’ future operations, see Part I, Item 1A, “Risk Factors,” in Lucid Diagnostics’ most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A,

“Risk Factors” in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid

Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Investor and Media Contact

Matt

Riley

Vice

President, Investor Relations

PAVmed and Lucid Diagnostics mjr@pavmed.com

## Financial statements

### Income Statement (For the three months ended June 30, — Lucid Non-GAAP Measures (in thousands except per-share amounts))

| | For the three months ended June 30, – 2026 | For the three months ended June 30, – 2025 | For the six months ended June 30, – 2026 | For the six months ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | 1,474 | 1,163 | 2,730 | 1,991 |
| Operating expenses | 14,275 | 12,547 | 27,644 | 25,862 |
| Other (Income) expense, net | -1,114 | -6,945 | 682 | 7,476 |
| Net Loss | -11,687 | -4,439 | -25,596 | -31,347 |
| Net income (loss) per common share, basic and diluted | -0.08 | -0.08 | -0.24 | -0.52 |
| Net loss attributable to common stockholders | -14,715 | -7,888 | -38,343 | -43,906 |
| Preferred Stock dividends and deemed dividends | 3,028 | 3,449 | 12,747 | 12,559 |
| Net income (loss) as reported | -11,687 | -4,439 | -25,596 | -31,347 |
| Adjustments: | Depreciation and amortization expense1 | 224 | 222 | 446 | 443 |
| Adjustments: | Interest expense, net2 | -73 | -104 | -137 | -162 |
| Adjustments: | EBITDA | -11,536 | -4,321 | -25,287 | -31,066 |
| Other non-cash or financing related expenses: | Stock-based compensation expense3 | 1,694 | 1,143 | 3,104 | 2,174 |
| Other non-cash or financing related expenses: | Operating expenses issued in stock1 | 29 | 73 | 57 | 147 |
| Other non-cash or financing related expenses: | Change in FV convertible debt2 | -1,041 | -6,841 | 819 | 7,638 |
| Other non-cash or financing related expenses: | Non-GAAP adjusted (loss) | -10,854 | -9,946 | -21,307 | -21,107 |
| Other non-cash or financing related expenses: | Basic and Diluted shares outstanding | 183,124 | 98,989 | 161,729 | 83,976 |
| Other non-cash or financing related expenses: | Non-GAAP adjusted (loss) income per share | -0.06 | -0.1 | -0.13 | -0.25 |

### Income Statement (For the three months ended June 30, (in thousands except per-share amounts))

| | For the three months ended June 30, – 2026 | For the three months ended June 30, – 2025 | For the six months ended June 30, – 2026 | For the six months ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Cost of revenues | 1,445 | 1,563 | 3,070 | 3,114 |
| Stock-based compensation expense3 | -14 | -38 | -128 | -109 |
| Net cost of revenues | 1,431 | 1,525 | 2,942 | 3,005 |
| Amortization of intangible assets | 105 | 105 | 210 | 210 |
| Sales and marketing | 5,757 | 4,007 | 10,777 | 8,076 |
| Stock-based compensation expense3 | -338 | -245 | -593 | -485 |
| Net sales and marketing | 5,419 | 3,762 | 10,184 | 7,591 |
| General and administrative | 5,776 | 5,617 | 11,188 | 11,779 |
| Depreciation expense | -119 | -117 | -236 | -233 |
| Operating expenses issued in stock | -29 | -73 | -57 | -147 |
| Stock-based compensation expense3 | -1,169 | -741 | -2,075 | -1,342 |
| Net general and administrative | 4,459 | 4,686 | 8,820 | 10,057 |
| Research and development | 1,192 | 1,255 | 2,399 | 2,683 |
| Stock-based compensation expense3 | -173 | -119 | -308 | -238 |
| Net research and development | 1,019 | 1,136 | 2,091 | 2,445 |
| Total operating expenses | 14,275 | 12,547 | 27,644 | 25,862 |
| Depreciation and amortization expense | -224 | -222 | -446 | -443 |
| Operating expenses issued in stock | -29 | -73 | -57 | -147 |
| Stock-based compensation expense3 | -1,694 | -1,143 | -3,104 | -2,174 |
| Net operating expenses | 12,328 | 11,109 | 24,037 | 23,098 |
